aTyr Pharma, Inc. – NASDAQ:LIFE
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
aTyr Pharma stock price monthly change
+18.01%
month
aTyr Pharma stock price quarterly change
-3.55%
quarter
aTyr Pharma stock price yearly change
-19.15%
year
aTyr Pharma key metrics
Market Cap | 131.12M |
Enterprise value | 58.10M |
P/E | -1.24 |
EV/Sales | 5.59 |
EV/EBITDA | -1.30 |
Price/Sales | 5.44 |
Price/Book | 0.79 |
PEG ratio | -0.12 |
EPS | -0.89 |
Revenue | N/A |
EBITDA | -57.00M |
Income | -53.92M |
Revenue Q/Q | N/A |
Revenue Y/Y | -52.79% |
Profit margin | -436.53% |
Oper. margin | -446.79% |
Gross margin | 0% |
EBIT margin | -446.79% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeaTyr Pharma stock price history
aTyr Pharma stock forecast
aTyr Pharma financial statements
| Jun 2023 | 0 | -12.33M | |
|---|---|---|---|
| Sep 2023 | 353K | -11.34M | -3212.46% |
| Dec 2023 | 4.31M | -14.76M | -342.06% |
| Mar 2024 | 235K | -15.49M | -6591.91% |
| Mar 2024 | 235K | -15.49M | -6591.91% |
|---|---|---|---|
| Sep 2025 | 0 | -15.40M | |
| Oct 2025 | 155.23K | -6.60M | -4256.73% |
| Dec 2025 | 144.87K | -5.28M | -3649.05% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 132747000 | 26.69M | 20.11% |
|---|---|---|---|
| Sep 2023 | 125069000 | 26.86M | 21.48% |
| Dec 2023 | 122067000 | 31.59M | 25.88% |
| Mar 2024 | 113251000 | 28.96M | 25.58% |
| Jun 2023 | -12.01M | -4.15M | 8.01M |
|---|---|---|---|
| Sep 2023 | -9.55M | 4.38M | 2.68M |
| Dec 2023 | -11.06M | 17.81M | 6.03M |
| Mar 2024 | -22.38M | -1.35M | 7.73M |
aTyr Pharma alternative data
| Aug 2023 | 65 |
|---|---|
| Sep 2023 | 65 |
| Oct 2023 | 65 |
| Nov 2023 | 65 |
| Dec 2023 | 65 |
| Jan 2024 | 65 |
| Feb 2024 | 65 |
| Mar 2024 | 56 |
| Apr 2024 | 56 |
| May 2024 | 56 |
| Jun 2024 | 56 |
| Jul 2024 | 56 |
aTyr Pharma other data
92.72%
+28.69%
of LIFE is owned by hedge funds
17
-18
26.34M
+7.99M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jul 2023 | 15000 | 0 |
| Nov 2023 | 15000 | 0 |
| Dec 2023 | 15000 | 0 |
| Feb 2024 | 0 | 1590 |
| May 2024 | 25000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | BROADFOOT JILL MARIE officer: Chief Fi.. | Common Stock | 5,000 | $1.79 | $8,950 | ||
Purchase | SHUKLA SANJAY director, officer.. | Common Stock | 20,000 | $1.81 | $36,140 | ||
Sale | BROADFOOT JILL MARIE officer: Chief Fi.. | Common stock | 1,590 | $1.69 | $2,687 | ||
Option | SHUKLA SANJAY director, officer.. | Common stock | 10,375 | N/A | N/A | ||
Option | SHUKLA SANJAY director, officer.. | Restricted Stock Unit | 10,375 | N/A | N/A | ||
Option | BROADFOOT JILL MARIE officer: Chief Fi.. | Common stock | 3,750 | N/A | N/A | ||
Option | BROADFOOT JILL MARIE officer: Chief Fi.. | Restricted Stock Unit | 3,750 | N/A | N/A | ||
Option | DENYES NANCY officer: General .. | Common stock | 2,688 | N/A | N/A | ||
Option | DENYES NANCY officer: General .. | Restricted Stock Unit | 2,688 | N/A | N/A | ||
Purchase | SHUKLA SANJAY director, officer.. | Common Stock | 12,000 | $1.18 | $14,136 |
| Patent |
|---|
Application COMPOSITIONS AND METHODS COMPRISING HISTIDYL-TRNA SYNTHETASE SPLICE VARIANTS HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES Filling date: 23 Jun 2021 Issue date: 31 Mar 2022 |
Application Filling date: 10 Jun 2021 Issue date: 31 Mar 2022 |
Grant Filling date: 7 Apr 2020 Issue date: 27 Jul 2021 |
Application Filling date: 2 Oct 2020 Issue date: 3 Jun 2021 |
Grant Utility: Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities Filling date: 19 Nov 2019 Issue date: 9 Mar 2021 |
Application Filling date: 19 Apr 2018 Issue date: 3 Dec 2020 |
Application Filling date: 7 Apr 2020 Issue date: 10 Sep 2020 |
Application COMPOSITIONS AND METHODS COMPRISING HISTIDYL-TRNA SYNTHETASE SPLICE VARIANTS HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES Filling date: 7 Apr 2020 Issue date: 23 Jul 2020 |
Application INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF SERYL-TRNA SYNTHETASES Filling date: 21 Nov 2019 Issue date: 23 Jul 2020 |
Grant Utility: Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Cysteinyl-tRNA synthetase Filling date: 19 Jun 2018 Issue date: 21 Jul 2020 |
| Quarter | Transcript |
|---|---|
| Q4 2023 14 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q4 2022 10 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 10 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 15 Aug 2022 | Q2 2022 Earnings Call Transcript |
-
When is aTyr Pharma's next earnings date?
Unfortunately, aTyr Pharma's (LIFE) next earnings date is currently unknown.
-
Does aTyr Pharma pay dividends?
No, aTyr Pharma does not pay dividends.
-
How much money does aTyr Pharma make?
aTyr Pharma has a market capitalization of 131.12M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 96.6% to 353K US dollars.
-
What is aTyr Pharma's stock symbol?
aTyr Pharma, Inc. is traded on the NASDAQ under the ticker symbol "LIFE".
-
What is aTyr Pharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of aTyr Pharma?
Shares of aTyr Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are aTyr Pharma's key executives?
aTyr Pharma's management team includes the following people:
- Dr. Sanjay S. Shukla Pres, Chief Executive Officer & Director(age: 53, pay: $702,050)
- Ms. Jill M. Broadfoot Chief Financial Officer(age: 63, pay: $516,110)
- Ms. Nancy E. Denyes Krueger Gen. Counsel & Corporation Sec.(age: 57, pay: $477,140)
-
How many employees does aTyr Pharma have?
As Jul 2024, aTyr Pharma employs 56 workers.
-
When aTyr Pharma went public?
aTyr Pharma, Inc. is publicly traded company for more then 10 years since IPO on 7 May 2015.
-
What is aTyr Pharma's official website?
The official website for aTyr Pharma is atyrpharma.com.
-
Where are aTyr Pharma's headquarters?
aTyr Pharma is headquartered at 3545 John Hopkins Court, San Diego, CA.
-
How can i contact aTyr Pharma?
aTyr Pharma's mailing address is 3545 John Hopkins Court, San Diego, CA and company can be reached via phone at 858 731 8389.
aTyr Pharma company profile:
aTyr Pharma, Inc.
atyrpharma.comExchange:
NASDAQ
Full time employees:
56
Industry:
Biotechnology
Sector:
Healthcare
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
3545 John Hopkins Court
San Diego, CA 92121
San Diego, CA 92121
CIK: 0001339970
ISIN: US0021202025
CUSIP: 002120202
